Contact
Office Hours
Mon – Fri : 9am – 5pm
© 2024 Advance Australia Care | Privacy Policy
| Drug Name: | Provigil / Modafinil |
| Tablet Strength: | 100-200 mg |
| Available Packages: | 30 - 180 pills |
| Payment Method: | VISA, MASTERCARD |
| Shipment: | US2US EU2EU international |
| Order Now: | Visit Pharmacy |
Provigil (modafinil) is a central nervous system stimulant approved for managing conditions such as narcolepsy, obstructive sleep apnea, and shift work sleep disorder. While generally considered safer than amphetamine-based stimulants, growing concerns exist regarding its non-prescribed use, particularly among students seeking to boost cognitive function and reduce sleep needs during intensive study periods. This report describes a 23-year-old female who presented to a cardiology clinic with recurrent episodes of palpitations and nausea that had started a week earlier. She had no significant medical history and denied alcohol, tobacco, or recreational drug use. However, she disclosed taking 100 mg of Provigil twice daily for the past month to enhance academic performance. Physical and neurological evaluations were unremarkable, though mild agitation and slightly accelerated speech were noted. Baseline blood work was within normal limits. Her electrocardiogram (ECG) revealed a sinus rhythm accompanied by a right bundle branch block (RBBB). Transthoracic echocardiography showed a preserved ejection fraction (60%) with no signs of structural heart disease. A 24-hour Holter monitor recorded 12,868 monomorphic premature ventricular contractions (PVCs) and 11 short episodes of non-sustained ventricular tachycardia (NSVT), with the longest run consisting of eight beats. Provigil was immediately discontinued. Two weeks post-discontinuation, the patient reported complete resolution of symptoms. Her follow-up ECG confirmed normal sinus rhythm, and the RBBB was no longer present. A repeated ambulatory ECG one month later recorded only 86 isolated PVCs, with no further evidence of NSVT. Although Provigil is widely regarded as having a more favorable cardiovascular profile compared to other stimulants, this case highlights the importance of monitoring for arrhythmic effects, especially in otherwise healthy individuals. Physicians should consider routine cardiac evaluation when initiating Provigil and discuss the risks of off-label use with patients, particularly among populations prone to misuse.
Are you looking for an NDIS Therapy Assistant? Look no further than Advance Australia Care.
Consent and Ethical Compliance The patient provided written informed consent for the publication of this case report and all accompanying clinical images. Pharmacological Background and Mechanisms Provigil (modafinil) is a wakefulness-promoting agent commonly prescribed for narcolepsy, shift work sleep disorder, and obstructive sleep apnea. Its action involves blocking dopamine and norepinephrine transporters, which elevates extracellular catecholamine levels. It also indirectly affects serotonin, histamine, GABA, and glutamate pathways. Compared to classical stimulants such as amphetamine derivatives, Provigil is generally considered to have fewer cardiovascular effects. Nevertheless, in cases of overdose or misuse, adverse reactions such as sinus tachycardia, chest discomfort, and hypertension have been documented. Even when used at therapeutic doses, isolated reports have noted an increase in premature ventricular contractions (PVCs). In non-sleep-deprived healthy adults, Provigil has been shown to improve certain aspects of executive functioning, learning, and memory, although its effect on creativity appears minimal. However, the drug’s off-label use as a cognitive enhancer—particularly among students—raises serious public health concerns. Our case highlights that even substances considered relatively safe can provoke serious arrhythmic events. This underscores the need for tighter regulation around the use and distribution of such medications. Pathophysiological Insights PVCs can originate from several mechanisms, with three primary theories most commonly accepted. The leading explanation involves triggered activity resulting from afterdepolarizations—electrical disturbances that occur when intracellular calcium levels rise abnormally. This phenomenon, known as delayed afterdepolarization (DAD), occurs during the repolarization phase of the cardiac cycle. DAD has been associated with factors such as digitalis toxicity, catecholaminergic polymorphic ventricular tachycardia, and excessive caffeine intake. Research suggests that central nervous system stimulants with amphetamine-like effects—such as Provigil—may also disrupt calcium homeostasis, leading to tachyarrhythmias. These stimulants increase sympathetic nervous system activity, which elevates cyclic AMP levels and activates protein kinase A. This, in turn, enhances intracellular calcium concentrations and generates oxidative stress. Chronic exposure to such biochemical changes may promote cellular damage through apoptosis, necrosis, and mitochondrial dysfunction. These effects may explain the reversible conduction abnormalities and arrhythmic presentations observed in this case, including the transient bundle branch block.
The presence of a right bundle branch block (RBBB) in this patient was unexpected, particularly given the absence of any structural heart abnormality. The most plausible explanation involves heightened sympathetic activity, which may have triggered a functional conduction delay specific to the right bundle. This phenomenon, previously described by Chilson et al., is known as a functional bundle branch block and can occur in response to elevated heart rates, where the right bundle remains relatively refractory compared to the left. RBBB of this kind has been documented even in individuals without underlying heart disease. Comparable cases have been reported. Binnenmars et al. described a patient who developed polymorphic non-sustained ventricular tachycardia (NSVT) while being treated with Provigil for narcolepsy. That individual had preexisting hypertension and chronic obstructive pulmonary disease, whereas our patient was otherwise healthy. Additionally, our case involved monomorphic NSVT and a concurrent RBBB, with no systemic disease or structural heart findings. In both instances, however, the arrhythmic episodes resolved following discontinuation of the medication, suggesting a strong temporal link. To further evaluate the scope of Provigil-associated arrhythmias, we conducted a review of the United States Food and Drug Administration's Adverse Event Reporting System (FAERS). This publicly accessible database compiles voluntary reports from healthcare professionals, manufacturers, and patients. Our search identified eight cases of ventricular tachycardia (VT) associated with Provigil, two of which resulted in death. While these findings are notable, it’s important to acknowledge the inherent limitations of spontaneous reporting systems, such as potential underreporting, reporting bias, and lack of confirmatory diagnostic data. In this case, all other known contributors to PVCs and NSVT—such as cardiac structural anomalies, endocrine disorders, and metabolic imbalances—were ruled out. Following the discontinuation of Provigil, the patient’s arrhythmias, including frequent PVCs and the RBBB pattern, resolved entirely. This supports a diagnosis of Provigil-induced arrhythmia. Although Provigil is perceived as having a safer cardiovascular profile than traditional stimulants, its growing misuse—particularly among students aiming to enhance cognitive performance and reduce sleep—is a cause for concern. While serious arrhythmias remain rare, especially in otherwise healthy individuals, clinicians should remain vigilant and inquire specifically about unsupervised or off-label use when evaluating unexplained cardiac symptoms.
By joining our community, you’re taking a step towards a world where everyone’s abilities are recognised and supported.
Mon – Fri : 9am – 5pm
Mon – Fri : 9am – 5pm
© 2024 Advance Australia Care | Privacy Policy